Skip to main content
Log in

Palonosetron

In the Prevention of Nausea and Vomiting

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists. Intravenous palonosetron is widely indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in the acute and delayed phases following moderately emetogenic chemotherapy (MEC) and the prevention of CINV in the acute phase following highly emetogenic chemotherapy (HEC). In the US, oral palonosetron is approved for the prevention of CINV in the acute phase following MEC (although this formulation is not currently available), and intravenous palonosetron is indicated for the prevention of postoperative nausea and vomiting (PONV) in the first 24 hours following surgery. All indications are currently limited to adult patients.

Intravenous palonosetron was noninferior to intravenous ondansetron (with statistically greater efficacy than ondansetron) or dolasetron in preventing CINV following MEC, or to intravenous ondansetron or granisetron in preventing CINV following HEC, in the acute phase. Statistically greater efficacy was seen with intravenous palonosetron than ondansetron or dolasetron in preventing CINV following MEC in the delayed phase. Oral palonosetron was noninferior to intravenous palonosetron in preventing CINV in the acute phase in patients receiving MEC. Intravenous palonosetron was superior to placebo in preventing PONV in the first 24 hours following surgery. Palonosetron was generally well tolerated in clinical trials. Intravenous palonosetron is a valuable option in the prevention of acute- and delayed-phase CINV in adult patients receiving MEC, and of acute-phase CINV in patients receiving HEC. Oral palonosetron is likely to be a useful addition to oral formulations of other 5-HT3 receptor antagonists in preventing CINV in patients receiving MEC. Intravenous palonosetron is a useful alternative to currently recommended agents in PONV prevention.

Pharmacological Properties

Although all 5-HT3 receptor antagonists prevent nausea and vomiting by selective inhibition of 5-HT3 receptors, palonosetron is structurally different to, and has a higher affinity for the 5-HT3 receptor than, the other 5-HT3 receptor antagonists; it is the only allosteric antagonist and has a long duration of action. Palonosetron has no clinically relevant effects on the cardiovascular system, including prolongation of the corrected QT interval.

The pharmacokinetic profile of intravenous palonosetron is generally similar between patients receiving chemotherapy and those undergoing surgery. Oral palonosetron has a bioavailability of 97%. Palonosetron is extensively distributed and is ≈62% bound to plasma proteins. Cytochrome P450 (CYP) accounts for ≈50% of palonosetron metabolism, mainly by CYP2D6, CYP3A4 and CYP1A2; the major metabolites have minimal antagonistic activity (<1%) at the 5-HT3 receptor. Palonosetron has a long terminal elimination half-life (mean ≈40 hours) and is excreted mainly through the urinary route. Dose adjustment of palonosetron is not needed on the basis of age, sex, race, renal or hepatic impairment, concurrent medication or clinical chemistry.

Therapeutic Efficacy

In randomized, double-blind, multicentre trials, intravenous palonosetron was noninferior to intravenous ondansetron or dolasetron in preventing CINV in the acute phase in patients receiving MEC, with statistically better efficacy than ondansetron or dolasetron in subsequent superiority analyses in the acute and delayed phases. Intravenous palonosetron was noninferior to intravenous ondansetron or granisetron in preventing CINV in the acute phase following HEC. Intravenous palonosetron in combination with dexamethasone with or without aprepitant was an effective CINV prophylactic regimen. Oral palonosetron was noninferior to intravenous palonosetron in preventing CINV in the acute phase in patients receiving MEC in another trial. Intravenous palonosetron was generally associated with better health-related quality-of-life outcomes compared with intravenous ondansetron or dolasetron in patients receiving MEC, or with intravenous ondansetron in patients receiving HEC. Superior efficacy of intravenous palonosetron over placebo in preventing PONV in the 0–24 hour time period was established in two other trials.

Pharmacoeconomic Considerations

Cost analyses modelled on two European hospital perspectives in patients receiving MEC or HEC suggested pharmacoeconomic benefits associated with the use of palonosetron compared with that of ondansetron or first-generation 5-HT3 receptor antagonists in the management of CINV. A large US observational study (in patients receiving various chemotherapy regimens) reported a more favourable financial impact following the use of palonosetron compared with that of ondansetron for preventing CINV.

Tolerability

In clinical trials, the intravenous and oral formulations of palonosetron were generally well tolerated in patients receiving chemotherapy, and intravenous palonosetron was generally well tolerated in surgical patients. The incidence of reported adverse events was low (all <10%), and the majority of these were of mild or moderate severity; no or few study withdrawals as a result of adverse events were attributed to study medication. Headache and constipation were among the most commonly reported adverse events with the use of palonosetron.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Fig. 2
Table IV
Fig. 3
Fig. 4
Table V
Table VI

Similar content being viewed by others

References

  1. Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf 2003; 26(4): 227–59

    Article  PubMed  CAS  Google Scholar 

  2. Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999 Sep; 91(3): 693–700

    Article  PubMed  CAS  Google Scholar 

  3. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008 Mar–Apr; 14(2): 85–93

    Article  PubMed  CAS  Google Scholar 

  4. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000; 59(2): 213–43

    Article  PubMed  CAS  Google Scholar 

  5. de Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76(8): 1055–61

    Article  PubMed  Google Scholar 

  6. Jenkins K, Grady D, Wong J, et al. Post-operative recovery: day surgery patients’ preferences. Br J Anaesth 2001 Feb; 86(2): 272–4

    Article  PubMed  CAS  Google Scholar 

  7. Stieler JM, Reichardt P, Riess H, et al. Treatment options for chemotherapy-induced nausea and vomiting: current and future. Am J Cancer 2003; 2(1): 15–26

    Article  CAS  Google Scholar 

  8. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007; 21(10): 813–33

    Article  PubMed  CAS  Google Scholar 

  9. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program study of 360 cancer patients treated in the community. Cancer 2003 Jun 1; 97(11): 2880–6

    CAS  Google Scholar 

  10. Gupta A, Wu CL, Elkassabany N, et al. Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery? A systematic review of randomized controlled trials. Anesthesiology 2003 Aug; 99(2): 488–95

    Article  PubMed  Google Scholar 

  11. Hesketh PJ. Chemotherpy-induced nausea and vomiting. N Engl J Med 2008 Jun 5; 358(23): 2482–94

    Article  PubMed  CAS  Google Scholar 

  12. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004; 64(10): 1125–32; discussion 1133-4

    Article  PubMed  CAS  Google Scholar 

  13. US FDA. Aloxi® (palonosetron hydrochloride) injection for intravenous use: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021372s008s010lbl.pdf [Accessed 2009 Jul 28]

  14. US FDA. Aloxi® (palonosetron hydrochloride) capsules: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022233LBL.pdf [Accessed 2009 Jul 28]

  15. Ho K-Y, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006 Dec; 19(6): 606–11

    Article  PubMed  Google Scholar 

  16. Rojas C, Grunberg S, Rosti G. Creating real benefit for patients at risk of nausea and vomiting: palonosetron from bench to bedside. Clin Adv Hematol Oncol 2007 Dec; 5 (12 Suppl. 19): 4–17

    Google Scholar 

  17. Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor [published erratum appears in Anesth Analg 2008 Oct; 107 (4): 1405]. Anesth Analg 2008 Aug; 107(2): 469–78

    Article  PubMed  CAS  Google Scholar 

  18. Eglen RM, Lee C-H, Smith WL, et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 1995 Feb; 114(4): 860–6

    Article  PubMed  CAS  Google Scholar 

  19. Lorusso V, Spedicato A, Petrucelli L, et al. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer. Epub 2009 Mar 18

  20. Wong EHF, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995 Feb; 114(4): 851–9

    Article  PubMed  CAS  Google Scholar 

  21. Morganroth J, Parisi S, Moresino C, et al. High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo [abstract no. 1156]. EJC Supplements 2007 Sep; 5(4): 158–9

    Google Scholar 

  22. European Medicines Agency. Aloxi® (palonosetron) 250 mg solution for injection: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/aloxi/H-563-PI-en.pdf [Accessed 2009 Mar 23]

  23. European Medicines Agency. European Public Assessment Report for Aloxi (palonosetron): scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/aloxi/056305en6.pdf [Accessed 2008 Nov 13]

  24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA1476.pdf [Accessed 2009 Apr 6]

  25. Stoltz R, Cyong J-C, Shah A, et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004 May; 44(5): 520–31

    CAS  Google Scholar 

  26. Hunt TL, Gallagher SC, Cullen MT, et al. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy patients. J Clin Pharmacol 2005 May; 45(5): 589–96

    Article  PubMed  CAS  Google Scholar 

  27. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007 Nov; 15(11): 1293–300

    Article  PubMed  Google Scholar 

  28. Stoltz R, Parisi S, Shah A, et al. Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004 Nov; 25(8): 329–37

    Article  PubMed  CAS  Google Scholar 

  29. Shah AK, Hunt TL, Gallagher SC, et al. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005 Apr; 21(4): 595–601

    Article  PubMed  CAS  Google Scholar 

  30. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004 Feb; 15(2): 330–7

    Article  PubMed  CAS  Google Scholar 

  31. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003 Dec 1; 98(11): 2473–82

    Article  PubMed  CAS  Google Scholar 

  32. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003 Oct; 14(10): 1570–7

    Article  PubMed  CAS  Google Scholar 

  33. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006 Sep; 17(9): 1441–9

    Article  PubMed  CAS  Google Scholar 

  34. Yu Z, Liu W, Wang L, et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 2009 Jan; 17(1): 99–102

    Article  PubMed  Google Scholar 

  35. Grunberg S, Voisin D, Zufferli M, et al. Oral palonosetron (PALO) is as effective as intravenous (IV) PALO: a phase 3 dose ranging trial in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract no. 1143]. EJC Supplements 2007 Sep 4; 5: 155. Plus poster presented at the 14th European Conference of Clinical Oncology; 2007 Sep 23–27; Barcelona

    Google Scholar 

  36. Candiotti KA, Kovac AL, Melson TI, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg 2008 Aug; 107(2): 445–51

    Article  PubMed  CAS  Google Scholar 

  37. Kovac AL, Eberhart L, Kotarski J, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008 Aug; 107(2): 439–44

    Article  PubMed  CAS  Google Scholar 

  38. White PF, Scuderi P. Prevention of postoperative nausea and vomiting (PONV): a dose-ranging study involving palonosetron, a potent 5-HT3 receptor antagonist [abstract no. A703]. Anesthesiology 2005 Oct; 103: eA703

    Google Scholar 

  39. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006 Sep; 4(8): 403–8

    PubMed  CAS  Google Scholar 

  40. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008 May 1; 112(9): 2080–7

    Article  PubMed  CAS  Google Scholar 

  41. Massa E, Astara G, Madeddu C, et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pretreated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit Rev Oncol Hematol 2009 Apr; 70(1): 83–91

    Article  PubMed  Google Scholar 

  42. Fabi A, Nole’ F, Roila F, et al. Comparison of palonosetron (PALO) plus dexamethasone on day 1, with or without dexamethasone on days 2 and 3, in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients treated with anthracycline/cyclophosphamide regimens [abstract no. 4088]. 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 10–14; San Antonio (TX)

  43. Clark O, Engel T, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatments: systematic review and meta-analysis [abstract no. e20620]. J Clin Oncol 2009 May; 27 (15 Suppl.): e 0620

    Google Scholar 

  44. Petru E, Andel J, Angleitner-Boubenizek L, et al. Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wien Med Wochenschr 2008; 158(5–6): 169–73

    Article  PubMed  Google Scholar 

  45. Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 2005 Sep–Oct; 3(5): 369–74

    PubMed  CAS  Google Scholar 

  46. Martin AR, Pearson JD, Cai B, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003 Aug; 11(8): 522–7

    Article  PubMed  CAS  Google Scholar 

  47. Lindley CM, Hirsch JD, O’Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992 Oct; 1(5): 331–40

    Article  PubMed  CAS  Google Scholar 

  48. Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the Functional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006 Jan; 4(1): 35–41, 52

    PubMed  Google Scholar 

  49. Boccia RV, Gonzalez EF, Pluzanska AG, et al. Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV) [abstract no. 20608]. J Clin Oncol 2008 May 20; 26 (15 Suppl. Pt I): e20608

    Google Scholar 

  50. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009 Feb; 10(2): 115–24

    Article  PubMed  CAS  Google Scholar 

  51. Grous JJ, Riegel E, Gabrail N, et al. Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) [abstract no. 9627]. J Clin Oncol 2009 May; 27 (15 Suppl.): 514s. Plus poster presented at the Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)

    Google Scholar 

  52. Celio L, Bajetta E, Denaro A, et al. Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): subgroup analysis from a randomized phase III trial [abstract no. 9620]. J Clin Oncol 2009 May; 27 (15 Suppl.): 513s

    Google Scholar 

  53. American Society of Anesthesiologists. ASA physical status classification system [online]. Available from URL: http://www.asahq.org/clinical/physicalstatus.htm [Accessed 2008 Dec 12]

  54. Tang J, D’Angelo R, White PF, et al. The efficacy of RS-25259, a long-acting selective 5-HT3 receptor antagonist, for preventing postoperative nausea and vomiting after hysterectomy procedures. Anesth Analg 1998 Aug; 87: 462–7

    PubMed  CAS  Google Scholar 

  55. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 Mar 3; 85(5): 365–76

    Article  PubMed  CAS  Google Scholar 

  56. Osoba D, Zee B, Pater J, et al. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994 Oct; 3(5): 353–64

    Article  PubMed  CAS  Google Scholar 

  57. Tarricone R, Girolami F. Economic evaluation of a nw antiemetic drug: palonosetron versus ondansetron; assessment of the drug price ratio in five European countries. Clin Drug Investig 2005; 25(9): 597–608

    Article  PubMed  Google Scholar 

  58. Ravasio R, Lucioni C. Economic evaluation of prevention of chemotherapy-induced nausea and vomiting (CINV): palonosetron versus first generation 5-HT3 receptor antagonists [in Italian]. Pharmacoeconomics Ital Res Articles 2007; 9(1): 21–30

    Google Scholar 

  59. Feinberg BA, Gilmore J, Haislip S, et al. Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting. Comm Oncol 2009 Feb; 6(2): 62–7

    Article  Google Scholar 

  60. Kovac A, Clerici G, Schernikau U, et al. Palonosetron, a novel 5HT3 antagonist, does not prolong QTc interval in patients undergoing surgery [abstract no. A287]. Anesthesiology 2007; 107: eA287

    Google Scholar 

  61. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006 Sep 20; 24(27): 4472–8

    Article  PubMed  CAS  Google Scholar 

  62. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. American Society of Clinical Oncology [published erratum appears in J Clin Oncol 2006 Nov 20; 24 (33): 5341–2]. J Clin Oncol 2006 Jun 20; 24(18): 2932–47

    Article  PubMed  CAS  Google Scholar 

  63. Herrstedt J, Roila F, ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009 May; 20 Suppl. 4: 156–8

    Article  PubMed  Google Scholar 

  64. Multinational Association of Supportive Care in Cancer. Perugia International Cancer conference VII: antiemetic guidelines (March 2008) [online]. Available from URL: http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.ppt [Accessed 2009 May 25]

  65. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: antiemesis (v.4.2009) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf [Accessed 2009 Sep 17]

  66. American Society of PeriAnesthesia Nurses PONV/PDNV Strategic Work Team. ASPAN’s evidence-based clinical practice guideline for the prevention and/or management of PONV/PDNV. J Perianesth Nurs 2006 Aug; 21(4): 230–50

    Article  Google Scholar 

  67. Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007 Dec; 105(6): 1615–28

    Article  PubMed  Google Scholar 

  68. de Wit R, de Boer AC, vd Linden GHM, et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001 Oct 19; 85(8): 1099–101

    Article  PubMed  Google Scholar 

  69. Navari RM. Pharmacological management of chemother-induced nausea and vomiting: focus on recent developments. Drugs 2009; 69(5): 515–33

    Article  PubMed  CAS  Google Scholar 

  70. Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are the all the same? CNS Drugs 2005; 19(3): 225–38

    Article  PubMed  CAS  Google Scholar 

  71. Raftopoulos H, Bria E, Gralla R, et al. Is there a preferred dose of palonosetron? Results of an abstracted data (AD) meta-analysis (MA) of all eight randomized double-blind (RDB) studies and the impact on guideline considerations [abstract no. 9636]. J Clin Oncol 2009 May; 27 (15 Suppl.): 517s. Plus poster presented at the Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)

    Google Scholar 

  72. Lesser M, Gralla R, Napolitano B, et al. Determining the preferred dose of the serotonin antagonist (5-HT3) palonosetron: results of an individualized patient data meta-analysis (MA) of 1,947 patients in all randomized double blind (RDB) trials [abstract no. e20512]. J Clin Oncol 2009 May; 27 (15 Suppl.): e20512

    Google Scholar 

  73. MASCC Antiemetic Study Group. MASCC/ESMO comittees II–IV combined statement #3: moderate [slide presentation]. MASCC/ISOO Annual Symposium; 2009 Jun 27; Rome

  74. Kadota R, Shen V, Messinger Y. Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized study [abstract no. 9570]. J Clin Oncol 2007 Jun 20; 25 Suppl. 18: 543

    Google Scholar 

  75. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 2008 Aug; 39(6): 601–6

    Article  PubMed  Google Scholar 

  76. Vanscoy GJ, Fortner B, Smith R, et al. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Commu Oncol 2005 Mar–Apr; 2(2): 127–32

    Article  Google Scholar 

  77. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005 Oct 20; 23(30): 7685–96

    Article  PubMed  CAS  Google Scholar 

  78. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsage de pointes: an overview. Drug Saf 2002; 25(4): 263–86

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lily P. H. Yang.

Additional information

Various sections of the manuscript reviewed by: G. Adiga, Department of Hematology and Medical Oncology, Montefiore Medical Center, Bronx, New York, USA; C.N. Andrews, Department of Gastroenterology, University of Calgary, Calgary, Alberta, Canada; C.C. Apfel, Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA; A.B. Benson III, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; L. Bergmann, Department of Internal Medicine II, Johann Wolfgang Goethe-University, Frankfurt, Germany; A. Chan, Department of Pharmacy, National University of Singapore, Singapore; K. Charalabopoulos, Department of Physiology, University of Ioannina, Ioannina, Greece; A.L. Kovac, Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas, USA; J.B. Leslie, Department of Anesthesiology, Mayo Clinic College of Medicine, Scottsdale, Arizona, USA; K. Leslie, Department of Anaesthesia, Royal Melbourne Hospital, Melbourne, Victoria, Australia; M. Marchetti, Hematology Unit, Hospital Cardinal Massaia, Asti, Italy; M. Vergo, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘palonosetron’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search term was ‘palonosetron’. Searches were last updated 23 September 2009.

Selection: Studies in patients who received palonosetron. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Palonosetron, chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, pharmacodynamics, pharmacoeconomics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, L.P.H., Scott, L.J. Palonosetron. Drugs 69, 2257–2278 (2009). https://doi.org/10.2165/11200980-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11200980-000000000-00000

Keywords

Navigation